Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update

Atyr PHARMA INC (NASDAQ:ATYR) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 2,920,000 shares, an increase of 34.6% from the November 30th total of 2,170,000 shares. Approximately 3.6% of the shares of the stock are sold short. Based on an average daily volume of 988,700 shares, the days-to-cover ratio is presently 3.0 days.

Atyr PHARMA Stock Performance

Shares of NASDAQ:ATYR traded down $0.03 during mid-day trading on Friday, reaching $3.74. 1,046,593 shares of the company’s stock were exchanged, compared to its average volume of 603,420. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a twelve month low of $1.38 and a twelve month high of $3.98. The firm has a market cap of $313.94 million, a price-to-earnings ratio of -3.98 and a beta of 1.07. The firm’s fifty day simple moving average is $3.26.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Analysts predict that Atyr PHARMA will post -0.89 EPS for the current fiscal year.

Analysts Set New Price Targets

ATYR has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Jefferies Financial Group assumed coverage on Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Wells Fargo & Company assumed coverage on Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price for the company.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.